A Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors

Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · May 3, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating whether a combination of two supplements, creatine and curcumin, can help patients with early cachexia, a condition that often occurs in people with advanced stomach and esophageal cancers. Cachexia leads to weight loss and a decline in health, making it harder for patients to cope with their cancer treatment. The goal of the study is to see if this combination can reduce inflammation, improve metabolism, maintain muscle mass, and ultimately enhance the quality of life for patients.

To participate in this trial, individuals must have advanced stomach or esophageal cancer that cannot be easily treated or has come back after treatment, and they must show signs of early cachexia, like unwanted weight loss and a lack of appetite. Participants will need to be between the ages of 18 and 75, and they must be willing to provide their informed consent to join the study. Throughout the trial, they will be monitored to assess how well the treatment works and how it affects their overall health. It's important to note that those with certain health issues or who have had specific treatments may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of advanced tumors of the upper digestive tract with untreatable or postoperative recurrence of esophageal and gastric cancer III-IV
• • Meet the diagnostic criteria of early cachexia (anorexia and metabolic changes, involuntary body mass reduction ≤5% within 6 months)
• • Radiotherapy, chemotherapy or immunotherapy in our hospital
• • Understand and fill in a variety of rating scales
• • Informed consent, voluntary participation in this study
• Exclusion Criteria:
• • Neoadjuvant chemotherapy patients
• • Intestinal obstruction or gastrointestinal bleeding
• • Severe heart, lung and renal insufficiency
• • Coagulopathy
• • Clinical diagnosis with diabetes and other metabolic diseases
• • The expected survival time is less than 1 month
• • With cognitive dysfunction or poor coordination
• • Allergy to creatine or curcumin
• • With a history of drug abuse
• • Doctors or researchers deem unsuitable for study participation